RxDoctor Payments Data

Lauren James, MD

Family Medicine · Fairfax, VANPI 1972815199

Payments from drug & device makers

$1,275in general payments, 2019–2025

Across 26 payments — averaging $49.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Viiv Healthcare Company$641
  • Sanofi-aventis U.S. LLC$226
  • Novo Nordisk$125
  • Theratechnologies Inc.$63
  • Gilead$61
  • UCB, Inc.$48
  • plus $110 from 5 others

What the payments were for

  • Food & beverage$1,275100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,275 in reported general payments places this provider in the 70th percentile of 2,553 family medicine providers in Virginia.

See all family medicine providers in Virginia

Medicare billing

Part B allowed, 2024
$8,008
Medicare patients
19
Services billed
121

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala161$637,154
GenvoyaElviteg/Cob/Emtri/Tenof Alafen68$281,362
JulucaDolutegravir/Rilpivirine55$187,534
TivicayDolutegravir Sodium64$177,242
DovatoDolutegravir Sodium/Lamivudine27$90,053
OdefseyEmtricitab/Rilpiviri/Tenof Ala17$88,563
PrezcobixDarunavir/Cobicistat20$57,788
TriumeqAbacavir/Dolutegravir/Lamivudi15$51,266
Darunavir14$8,905
Emtricitabine-Tenofovir DisopEmtricitabine/Tenofovir (Tdf)18$797
Albuterol Sulfate HfaAlbuterol Sulfate20$632
Atorvastatin Calcium59$379
Amlodipine Besylate48$259
Fluticasone Propionate21$240
Rosuvastatin Calcium21$173

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy, Genvoya$61$918,516229 claims
Viiv Healthcare CompanyJuluca, Tivicay, Dovato, Triumeq$641$506,095161 claims
Johnson & JohnsonPrezcobix$21$57,78820 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 2,553 family medicine providers in Virginia.

Other family medicine in Fairfax

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →